Russell Investments Group Ltd. Boosts Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Russell Investments Group Ltd. boosted its position in Repligen Co. (NASDAQ:RGEN) by 1.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,172 shares of the biotechnology company’s stock after buying an additional 669 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.10% of Repligen worth $8,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in RGEN. UMB Bank n.a. lifted its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Repligen during the 4th quarter worth about $216,000. Van ECK Associates Corp boosted its stake in Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after purchasing an additional 3,066 shares during the period. Stephens Investment Management Group LLC grew its holdings in Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after buying an additional 37,057 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in shares of Repligen during the third quarter valued at about $233,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Repligen stock opened at $122.86 on Friday. The firm has a market capitalization of $6.90 billion, a PE ratio of -240.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The firm has a 50-day moving average price of $143.12 and a 200-day moving average price of $146.32. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, April 4th. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $178.64.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.